Webinar: ADC and Immune Checkpoint Combination Therapies

ADC and Immune Checkpoint Combination Therapies

ADCs in combination offer a multifaceted strategy for tackling cancer, providing new avenues for treatment and addressing some of the challenges associated with single-agent therapies. The evolving landscape of combination therapies underscores the importance of ongoing research and clinical trials.

Comparing the new combination trials studying ADCs with chemotherapies and immune checkpoint modulators (ICMs) shows that the combination with ICMs has observed a strong uptrend in the last two years.

ADC and Immune Checkpoint Combination Therapy Webinar

In this webinar, we unlock the landscape of this promising space and delve into how this could shape the future of ADC drugs. Watch the recording now.

View Webinar

Our Experts

Jia He

House Speaker

ADC Technical Lead

Beacon

Eleni Taoula

Moderator

Account Manager

Beacon

You May Also Be Interested In…

ADC H1 2026 Landscape Review

Access Review

Webinar date: 29/09/2026

Multi-Payload ADCs: Breakthrough Innovation or Unproven Opportunity? Insights from Beacon’s New Market Report

5th Targeted Radiopharmaceuticals Summit US 2026 Presentation

Access Report

View All

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration